Alvotech
General ticker "ALVO" information:
- Sector: Health Care
- Industry: Drug Manufacturers - Specialty & Generic
- Capitalization: $1.9B (TTM average)
Alvotech does not follow the US Stock Market performance with the rate: -28.9%.
Estimated limits based on current volatility of 2.3%: low 3.24$, high 3.39$
Factors to consider:
- Total employees count: 947 as of 2022
- Price in estimated range
- Earnings for 3 months up through Q1 are below our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-12-31 to 2027-12-31
- 2025-12-31 to 2026-12-31 estimated range: [2.70$, 6.74$]
- 2026-12-31 to 2027-12-31 estimated range: [2.47$, 6.04$]
Financial Metrics affecting the ALVO estimates:
- Positive: with PPE of 50.1 at the end of fiscal year the price was low
- Negative: negative Operating cash flow
- Positive: 7.57 < Operating profit margin, % of 13.34
- Positive: Industry inventory ratio change (median), % of 0.12 <= 0.28
- Positive: -14.27 < Investing cash flow per share per price, % of -7.45
- Positive: 1.77 < Return on assets ratio (scaled to [-100,100]) of 1.84
Short-term ALVO quotes
Long-term ALVO plot with estimates
Financial data
| YTD | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|
| Operating Revenue | $91.43MM | $489.68MM | $586.32MM |
| Operating Expenses | $446.29MM | $420.04MM | $508.11MM |
| Operating Income | $-354.86MM | $69.64MM | $78.21MM |
| Non-Operating Income | $-296.19MM | $-287.21MM | $58.14MM |
| Interest Expense | $134.82MM | $157.60MM | $149.19MM |
| R&D Expense | $210.83MM | $171.31MM | $184.19MM |
| Income(Loss) | $-651.05MM | $-217.56MM | $136.35MM |
| Taxes | $-99.32MM | $14.30MM | $108.43MM |
| Net Income(Loss)* | $-551.73MM | $-231.86MM | $27.92MM |
| Stockholders Equity | $-932.49MM | $-412.77MM | $-284.49MM |
| Inventory | $74.43MM | $127.89MM | $220.05MM |
| Assets | $950.09MM | $1,221.40MM | $1,487.10MM |
| Operating Cash Flow | $-312.19MM | $-236.84MM | $-50.20MM |
| Capital expenditure | $46.47MM | $57.00MM | $64.47MM |
| Investing Cash Flow | $-46.34MM | $-18.87MM | $-104.22MM |
| Financing Cash Flow | $301.32MM | $297.31MM | $270.83MM |
| Earnings Per Share** | $-2.43 | $-0.87 | $0.10 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.